Can Compounding Pharmacies Compound BPC-157?

The short answer

No — as of 2026, a licensed US compounding pharmacy generally cannot lawfully compound BPC-157. This is not a matter of opinion or of an individual pharmacy's caution; it follows directly from the structure of federal compounding law. A pharmacy that compounds from raw active ingredient (a "bulk drug substance") is only permitted to do so when that ingredient qualifies under one of a small set of defined pathways, and BPC-157 does not qualify under any of them.

The clearest way to understand this is to look at the exact three-part test the law sets out, then hold BPC-157 up against each part. When you do, the answer becomes almost mechanical: the compound fails the first test, then the second, then the third. Nothing about it being "just a peptide" or "widely available for research" changes that analysis. For the broader legal picture, see our companion explainer, is BPC-157 legal in 2026?.

What compounding is — and what a "bulk substance" means

Pharmacy compounding is the practice of combining, mixing, or altering ingredients to create a medication tailored to an individual. It is a long-standing and legitimate part of pharmacy — used, for example, to make a liquid version of a drug for someone who cannot swallow tablets, or to remove a dye a person reacts to. Compounding is not the same as manufacturing: a compounder prepares a specific preparation, generally in response to a prescription, rather than mass-producing a standardized product.

A compounder can start from two very different kinds of raw material. The first is a finished, FDA-approved drug that is simply reformulated. The second is a bulk drug substance — the raw active pharmaceutical ingredient itself, in powder form, before it has ever been made into an approved product. BPC-157 falls squarely into this second category: there is no approved BPC-157 drug to reformulate, so any compounding would have to begin from bulk powder. That single fact is what pulls BPC-157 into the strictest part of the law.

The reason bulk substances are tightly controlled is straightforward. When a pharmacy compounds from an approved drug, the FDA has already vetted that drug's safety, purity, and manufacturing. When a pharmacy starts from raw bulk powder, none of that vetting exists — so Congress built a gatekeeping system to decide which bulk substances are acceptable at all. To see where BPC-157 sits scientifically before the legal layer, review our BPC-157 research profile and how BPC-157 works.

The law that governs this: 503A and the DQSA

The framework comes from the Drug Quality and Security Act of 2013 (DQSA), which Congress passed after a deadly 2012 meningitis outbreak traced to contaminated compounded injections. The DQSA formalized FDA oversight of compounding through two sections of the Federal Food, Drug, and Cosmetic (FD&C) Act: Section 503A, which covers traditional, patient-specific compounding by pharmacies, and Section 503B, which covers larger "outsourcing facilities."

Section 503A is the one that matters for a pharmacy filling a prescription for an individual. It says, in effect, that a pharmacy may compound using a bulk drug substance only if that substance satisfies at least one of three conditions — the "503A(b)" sourcing paths. If a bulk substance meets none of them, the pharmacy is not permitted to compound with it, full stop. We cover the whole system in depth in what the FDA 503A bulks list is.

The three sourcing paths in plain terms

1. The bulk substance is the subject of an applicable USP or NF monograph (an official United States Pharmacopeia / National Formulary quality standard).
2. The bulk substance is a component of an FDA-approved drug.
3. The bulk substance appears on the FDA's 503A bulks list — a list the agency maintains of substances that may be used in compounding even without a monograph or approved-drug link.

These three paths are alternatives, not requirements to satisfy all at once — a substance only needs to clear one. That makes the analysis for BPC-157 unusually clean, because it happens to miss on every path. The sections that follow take them one at a time.

How BPC-157 fails all three 503A paths

Path 1 — no USP or NF monograph

A USP monograph is a published, enforceable quality standard: it specifies identity, strength, purity, and testing methods for a substance. Compounding from a substance with a monograph gives the pharmacy an objective yardstick for what "acceptable" material looks like. BPC-157 has no applicable USP or NF monograph. There is no official standard defining what pharmaceutical-grade BPC-157 even is, which means the first sourcing path is simply unavailable.

Path 2 — not a component of an approved drug

The second path allows compounding from a bulk substance that is an active ingredient in some FDA-approved product. This is common for well-established molecules. BPC-157, however, has never been the subject of an approved new drug application, and it is not an ingredient in any approved drug. Because no approved BPC-157 product exists, there is nothing for this path to attach to. This connects to a point we make in research peptides vs prescription peptides: the absence of an approval is not a technicality — it is the whole reason the clinical channel is closed.

Path 3 — Category 2 on the bulks list, not Category 1

The third path is the FDA's dedicated 503A bulks list. When a substance is nominated for this list, the FDA sorts it, on an interim basis, into one of two buckets while it completes review. Category 1 substances may be used in compounding during that review. Category 2 substances are those for which the FDA has identified significant safety concerns, and the agency's position is that they should not be used in compounding while under review. BPC-157 was placed in Category 2. That placement is what forecloses the third path — it is on the list, but on the wrong side of it.

Put the three together and the conclusion is unavoidable: with no monograph, no approved-drug link, and a Category 2 placement rather than an approved-list or Category 1 status, BPC-157 clears none of the doors the law provides. A pharmacy has no lawful route to compound it under 503A.

What Category 2 actually means

Category 2 is easy to misread, so it is worth being precise. It does not mean the substance has been formally banned by rulemaking, and it does not mean the FDA has finished its evaluation. It is an interim designation: the agency has reviewed the available data, identified significant safety concerns, and taken the position that pharmacies should not compound the substance while the review continues. For BPC-157, the concerns the FDA has cited relate to insufficient safety data, questions about how the peptide is characterized, and potential immunogenicity.

The practical effect is the same as a prohibition for day-to-day purposes: a pharmacy compounding a Category 2 substance is compounding outside the conditions of 503A, which exposes both the preparation and the pharmacy to FDA enforcement. This is why the Category 2 label — not the Controlled Substances Act, and not any criminal statute — is the specific mechanism that keeps BPC-157 out of legitimate pharmacies. From roughly 2020 through 2023–2024 the FDA placed a number of research peptides into Category 2, including BPC-157, TB-500 (thymosin beta-4), Ipamorelin, CJC-1295, and GHK-Cu.

503A vs 503B: why outsourcing facilities can't supply it either

A natural follow-up question is whether a larger, more heavily regulated compounder — a 503B outsourcing facility — could step in where a 503A pharmacy cannot. The answer is still no, and for a similar reason. Section 503B facilities operate under current good manufacturing practice (cGMP) standards and can produce compounded preparations in larger batches without a patient-specific prescription, but they are bound by an even more restrictive bulk-substance rule.

A 503B facility may generally compound from a bulk drug substance only if there is a clinical need for it and it appears on the FDA's separate 503B bulks list, or if it is used to address a drug shortage. BPC-157 is not on the 503B list, and it is not a shortage drug. So the outsourcing-facility route, far from being a workaround, is a narrower gate than the pharmacy route. Neither the 503A nor the 503B channel can lawfully deliver BPC-157 in 2026.

So why do some clinics claim to offer it?

Despite all of the above, it is not hard to find websites, wellness clinics, and "peptide therapy" practices that advertise BPC-157 as if it were a routine compounded preparation. Understanding how that happens is useful, because it clarifies what is really being sold. In almost every case, one of a few things is going on.

• The product is being sold as a research-use-only (RUO) chemical, explicitly not for human consumption — and the marketing quietly blurs that line. We unpack this in why peptides are research-only.
• The seller is a supplier operating outside the compounding framework entirely, sourcing bulk powder and shipping it as a reagent. Our guide to whether peptide suppliers are legit explains what verification actually looks like.
• A clinic is compounding or dispensing it anyway, in contravention of the Category 2 designation — which is precisely the enforcement risk the framework is designed to catch.

The takeaway is that "compounded BPC-157 from a licensed pharmacy" is, as of 2026, essentially a contradiction in terms. A legitimate 503A pharmacy following the law will not compound a Category 2 substance. So an offer of "pharmacy-compounded BPC-157" should prompt questions rather than reassurance, and any material claiming it is approved or clinically sanctioned should be treated with skepticism.

What would have to change — and the July 2026 review

For a pharmacy to lawfully compound BPC-157, at least one of the three sourcing paths would have to open. In practice that means one of the following: the USP would publish a monograph establishing a quality standard; an FDA-approved BPC-157 drug would come to exist (making it a component of an approved product); or the FDA would move BPC-157 off Category 2 — either onto the approved 503A bulks list or into Category 1. Each of those is a substantial regulatory step, and none happens quickly.

This is where the current news cycle comes in. On April 15, 2026, the FDA announced it would convene an advisory committee to reconsider its restrictions on several compounding peptides, BPC-157 among them. That committee is scheduled to meet on July 23, 2026 — upcoming as of this writing. It is important to be exact about what such a committee does: it issues a non-binding recommendation. The FDA is not required to adopt it, and even a favorable recommendation would take months to translate into any change to BPC-157's Category 2 status.

In other words, the July meeting is a step in a process, not a decision, and nothing about the compounding rules has changed as of mid-2026. We track the meeting itself in the FDA peptide update for July 2026, explain the mechanics of what a committee vote does and does not do in what happens after an FDA advisory committee vote, and give the wider context in the FDA peptide ban reversal explainer.

What this means in practice

For anyone trying to make sense of the landscape, the honest summary is that there is no lawful clinical supply of BPC-157 in the US as of 2026. It cannot be prescribed and compounded through the normal channels, which is why the entire market for it exists in the research-use-only space rather than in pharmacies.

• Recognize that a Category 2 designation, not a criminal statute, is what blocks lawful compounding — so "it isn't a controlled substance" does not mean a pharmacy may make it.
• Be wary of any clinic or site marketing "compounded" or "pharmaceutical-grade" BPC-157; a compliant 503A pharmacy will not compound a Category 2 substance.
• If you are following the research literature, use neutral educational tools like our reconstitution and dosing calculator to understand study methods — not as medical instructions.
• Read the companion pieces on BPC-157's overall legal status and the 503A bulks list to see how the pieces fit together.
• Track primary sources and re-check before assuming anything has changed; bookmark the FDA compounding pages.